Entity

Time filter

Source Type


Facchini E.,Catheterization Laboratory and Coronary Care Unit | Degiovanni A.,University of Piemonte Orientale | Cavallino C.,ASL Vercelli | Lupi A.,Catheterization Laboratory and Coronary Care Unit | And 2 more authors.
Cardiovascular and Hematological Agents in Medicinal Chemistry | Year: 2015

Many clinically important differences exist between beta blockers. B1-selectivity is of clinical interest because at clinically used doses, b1- selective agents block cardiac b-receptors while having minor effects on bronchial and vascular b-receptors. Beta-adrenergic blocking agents significantly decrease the frequency and duration of angina pectoris, instead the prognostic benefit of beta-blockers in stable angina has been extrapolated from studies of post myocardial infarction but has not yet been documented without left ventricular disfunction or previous myocardial infarction. Organic nitrates are among the oldest drugs, but they still remain a widely used adjuvant in the treatment of symptomatic coronary artery disease. While their efficacy in relieving angina pectoris symptoms in acute settings and in preventing angina before physical or emotional stress is undisputed, the chronic use of nitrates has been associated with potentially important side effects such as tolerance and endothelial dysfunction. B-blockers are the firstline anti-anginal therapy in stable stable angina patients without contraindications, while nitrates are the secondline anti-anginal therapy. Despite 150 years of clinical practice, they remain fascinating drugs, which in a chronic setting still deserve investigation. This review evaluated pharmacotherapy and indications of Beta-blockers and nitrates in stable angina. © 2015 Bentham Science Publishers. Source


Rognoni A.,Catheterization Laboratory and Coronary Care Unit | Cavallino C.,ASL Vercelli | Veia A.,Catheterization Laboratory and Coronary Care Unit | Bacchini S.,Catheterization Laboratory and Coronary Care Unit | And 7 more authors.
Cardiovascular and Hematological Agents in Medicinal Chemistry | Year: 2015

Cardiovascular diseases and in particular coronary atherosclerotic disease are the leading cause of mortality and morbidity in the industrialized countries. Coronary atherosclerosis has been recognized for over a century and it was the subject of various studies. Pathophysiological studies have unravelled the interactions of molecular and cellular elements involved in atherogenesis; during the last decades the basic research has focused on the study of the instability of atherosclerotic plaque. Plaque rupture and resulting intracoronary thrombosis are thought to account for most acute coronary syndromes including ST – segment elevation myocardial infarction and non ST – segment elevation myocardial infarction. This is a brief review of the pathophysiology of atherosclerotic plaque development. © 2015 Bentham Science Publishers. Source


Cavallino C.,ASL Vercelli | Facchini M.,Catheterization Laboratory and Coronary Care Unit | Veia A.,Catheterization Laboratory and Coronary Care Unit | Bacchni S.,Catheterization Laboratory and Coronary Care Unit | And 5 more authors.
Cardiovascular and Hematological Agents in Medicinal Chemistry | Year: 2015

Chronic angina represents a condition that impairs quality of life and is associated with decreased life expectancy in the industrialized countries. Current therapies that reduce angina frequency include old drugs such as nitrates, β -blockers and calcium antagonists. Several new investigational drugs are being tested for the treatment of chronic angina. This review will focus on ranolazine, a drug approved by the US Food and Drug Administration (FDA) in 2006 for patients with chronic angina who continue to be symptomatic despite optimized therapies. The main molecular mechanism underlying ranolazine-mediated beneficial effects has been identified as inhibition of the late Na+ current during the action potential, which potentially improves oxygen consumption, diastolic dysfunction and coronary blood flow. The aim of this review is to update the evidence for ranolazine treatment in chronic angina and discuss its therapeutic perspectives based on the most recent clinical and experimental studies. © 2015 Bentham Science Publishers. Source

Discover hidden collaborations